An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...
GlobalData on MSN
Amgen buys Dark Blue Therapeutics in $840m oncology deal
According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...
Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...
Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...
Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...
Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...
Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...
Zacks Investment Research on MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding ...
Amgen (NASDAQ:AMGN) remains a major biotechnology name as nasdaq composite discussions highlight healthcare innovation.
Amgen is getting down with Disco Pharmaceuticals, commissioning the German outfit to work on cancer therapies focused on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback